Endiatx, a leading Silicon Valley medical technology company, is pioneering healthcare advancements with their innovative micro-robotics designed for internal use.

Their flagship product, PillBot™, is a small, wireless device engineered to navigate the human stomach, promising to lower costs and improve access to essential medical diagnostics and treatments.

About the size of a standard vitamin pill, PillBot™ streams live video as it maneuvers through the stomach's fluid environment.

Following a short fasting period, patients swallow PillBot™, allowing a remote physician connected via the internet to guide its exploration using a controller.

This approach eliminates the need for sedation and hospital visits for many patients, particularly in cases where traditional upper endoscopies fail to provide conclusive results.

Endiatx, under the leadership of Co-Founder, who chairs Gastroenterology at the Mayo Clinic, showcased PillBot™ at TED and Amazon MARS conferences.

Dr. Kumbhari's live demonstration inside Endiatx Chairman Alex Luebke's stomach highlighted the device's potential to significantly enhance medical care through remote diagnostics.

PillBot™ is expected to complete clinical trials by late 2024, aiming for FDA clearance by 2025 and commercial launch in the US by early 2026.

It is also poised for international expansion, especially in developing nations where access to comprehensive medical facilities is limited, providing critical diagnostic capabilities.

Future advancements integrating AI for enhanced movement, automation, and diagnostic precision will further streamline routine screenings and acute care with PillBot™ and its successors.

These innovations promise earlier detection of conditions such as stomach cancer, potentially saving countless lives worldwide each year.

 

 

 

 

Source: prnewswire.com

Report Abuse